Estimated Acquisition Cost Differences between Fixed and Simulated Body Weight-Based Nivolumab Dosing Using Real-World Claims Data in Japan
Open Access
- 17 September 2026
- journal article
- research article
- Published by Springer Nature in Drugs - Real World Outcomes
- p. 1-9
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and pembrolizumabThe Lancet Oncology, 2022
- Economics of alternative dosing strategies for pembrolizumab and nivolumab at a single academic cancer centerCancer Medicine, 2020
- Less is more: a cost benefit analysis of a changed posology for nivolumabEuropean Journal of Clinical Pharmacology, 2020
- Switch to anti-programmed cell death protein 1 (anti-PD-1) fixed-dose regimen: What is the economic impact?European Journal of Cancer, 2019
- Personalized Dosing Versus Fixed Dosing of Immune Checkpoint Inhibitors: A Cost Analysis StudyAmerican Journal of Therapeutics, 2018
- Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancerAnnals of Oncology, 2018
- Dose Rationalization of Pembrolizumab and Nivolumab Using Pharmacokinetic Modeling and Simulation and Cost AnalysisClinical Pharmacology & Therapeutics, 2017
- Nivolumab Exposure–Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non–Small Cell Lung CancerClinical Cancer Research, 2017
- Assessment of nivolumab benefit–risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumorsAnnals of Oncology, 2017
- The future of immune checkpoint therapyScience, 2015